Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3109/15412555.2011.651180 http://scihub22266oqcxt.onion/10.3109/15412555.2011.651180 C4904720!4904720!22360383     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       COPD 2012 ; 9 (3): 268-75 Nephropedia Template TP {{tp|p=22360383|t=2012. Sildenafil for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Trial |pdf=|usr=}}{{22360383}} gab.com Text Sildenafil for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Trial JO: COPD http://www.kidney.de/pget.php?&tw=1&pmid=22360383 #FOAvip Rationale: Pulmonary hypertension with exercise is common in chronic obstructive pulmonary disease (COPD) and may contribute to exercise limitation in this disease. We aimed to determine the effects of treatment with sildenafil on exercise capacity in patients with COPD and emphysema. Methods: We performed a randomized, double-blind, placebo-controlled 2-period crossover trial of sildenafil thrice daily in ten adults with COPD and emphysema on CT scan without pulmonary hypertension. We randomized study participants to 4 weeks of sildenafil (or placebo) followed by a 1-week washout and then 4 weeks of placebo (or sildenafil). The 2 primary outcomes were the 6-minute walk distance and oxygen consumption at peak exercise. Results: Sildenafil had no effect on 6-minute walk distance (placebo-corrected difference = ?7.8 m, 95% confidence interval, ?23.2 to 7.5 m, p = 0.35) or oxygen consumption at peak exercise (placebo-corrected difference = ?0.1 ml/kg/min, 95% confidence interval ?2.1 to 1.8 ml/kg/min, p = 0.89). Sildenafil increased the alveolar-arterial oxygen gradient (p = 0.02), worsened symptoms (p = 0.04), and decreased quality-of-life (p = 0.03). Adverse events were more frequent while receiving sildenafil (p = 0.005). Conclusions: Routine sildenafil administration did not have a beneficial effect on exercise capacity in patients with COPD and emphysema without pulmonary hypertension. Sildenafil significantly worsened gas exchange at rest and quality of life. (clinicaltrials.gov NCT00104637). Twit Text FOAVip Sildenafil for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Trial ????COPD http://www.kidney.de/pget.php?&tw=1&pmid=22360383 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=22360383 #FOAvip English Wikipedia <ref>{{Cite pmid|22360383}}</ref> Sildenafil for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Trial #MMPMID22360383 Lederer DJ; Bartels MN; Schluger NW; Brogan F; Jellen P; Thomashow BM; Kawut SM COPD 2012[Jun]; 9 (3): 268-75 PMID22360383show ga Rationale: Pulmonary hypertension with exercise is common in chronic obstructive pulmonary disease (COPD) and may contribute to exercise limitation in this disease. We aimed to determine the effects of treatment with sildenafil on exercise capacity in patients with COPD and emphysema. Methods: We performed a randomized, double-blind, placebo-controlled 2-period crossover trial of sildenafil thrice daily in ten adults with COPD and emphysema on CT scan without pulmonary hypertension. We randomized study participants to 4 weeks of sildenafil (or placebo) followed by a 1-week washout and then 4 weeks of placebo (or sildenafil). The 2 primary outcomes were the 6-minute walk distance and oxygen consumption at peak exercise. Results: Sildenafil had no effect on 6-minute walk distance (placebo-corrected difference = ?7.8 m, 95% confidence interval, ?23.2 to 7.5 m, p = 0.35) or oxygen consumption at peak exercise (placebo-corrected difference = ?0.1 ml/kg/min, 95% confidence interval ?2.1 to 1.8 ml/kg/min, p = 0.89). Sildenafil increased the alveolar-arterial oxygen gradient (p = 0.02), worsened symptoms (p = 0.04), and decreased quality-of-life (p = 0.03). Adverse events were more frequent while receiving sildenafil (p = 0.005). Conclusions: Routine sildenafil administration did not have a beneficial effect on exercise capacity in patients with COPD and emphysema without pulmonary hypertension. Sildenafil significantly worsened gas exchange at rest and quality of life. (clinicaltrials.gov NCT00104637). äSildenafil for Chronic Obstructive Pulmonary Disease: A Randomized Cro(epmc).pdf DeepDyve Pubget Overpricing